|
Indian Society for Clinical Research (ISCR) has urged the Union government to prioritise the growth of India’s clinical research sector in the Union Budget 2026, calling for targeted policy support, increased funding, and regulatory reforms to strengthen the country’s research ecosystem. The industry body said sustained government intervention is critical to enhance India’s global competitiveness, accelerate innovation, and ensure faster access to safe and effective therapies for patients.
Dr Seema Pai, president, Indian Society for Clinical Research, said, “As we get closer to the Union Budget 2026, we have a strong opportunity to strengthen the clinical research ecosystem of India by increasing investment in academic research, infrastructure, and skill development.”
Major support for AI-enabled clinical trial data collection and analysis, digital health tool use and collaboration between academia and industry can help in speeding evidence-based healthcare and enable the industry to achieve the target of reaching US$ 120-130 billion by 2030 and ultimately US$ 450 billion by 2047, she added.
Streamlining regulations and incentives for research-led innovation, operational ease of import for technology used in these clinical trials will strengthen India’s position as a trusted global hub for high-quality, ethical clinical research, while ultimately improving patient outcomes. A key pillar of research is a focus on public-private partnerships among academic institutions, policymakers, and patients. This collaboration should aim to ensure evidence-based data generation, leveraging technology and maintaining a strong emphasis on quality, said Dr Pai.
|